155 related articles for article (PubMed ID: 8807077)
1. In vitro activities in new oxazolidinone antimicrobial agents against enterococci.
Eliopoulos GM; Wennersten CB; Gold HS; Moellering RC
Antimicrob Agents Chemother; 1996 Jul; 40(7):1745-7. PubMed ID: 8807077
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.
Noskin GA; Siddiqui F; Stosor V; Hacek D; Peterson LR
Antimicrob Agents Chemother; 1999 Aug; 43(8):2059-62. PubMed ID: 10428937
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Steckelberg JM
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.
Zurenko GE; Yagi BH; Schaadt RD; Allison JW; Kilburn JO; Glickman SE; Hutchinson DK; Barbachyn MR; Brickner SJ
Antimicrob Agents Chemother; 1996 Apr; 40(4):839-45. PubMed ID: 8849237
[TBL] [Abstract][Full Text] [Related]
5. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.
Jones RN; Johnson DM; Erwin ME
Antimicrob Agents Chemother; 1996 Mar; 40(3):720-6. PubMed ID: 8851600
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
Rybak MJ; Cappelletty DM; Moldovan T; Aeschlimann JR; Kaatz GW
Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of linezolid combined with minocycline against vancomycin-resistant Enterococci.
Wu J; Jiang TT; Su JR; Li L
Chin Med J (Engl); 2013 Jul; 126(14):2670-5. PubMed ID: 23876894
[TBL] [Abstract][Full Text] [Related]
8. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.
Livermore DM; Mushtaq S; Warner M; Woodford N
J Antimicrob Chemother; 2009 Apr; 63(4):713-5. PubMed ID: 19164418
[TBL] [Abstract][Full Text] [Related]
9. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.
Johnson AP; Warner M; Livermore DM
J Antimicrob Chemother; 2000 Feb; 45(2):225-30. PubMed ID: 10660506
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of the new oxazolidinone AZD2563 against Enterococci.
Eliopoulos GM; Wennersten CB; Moellering RC
Antimicrob Agents Chemother; 2002 Oct; 46(10):3273-5. PubMed ID: 12234858
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species.
Jorgensen JH; McElmeel ML; Trippy CW
Antimicrob Agents Chemother; 1997 Feb; 41(2):465-7. PubMed ID: 9021209
[TBL] [Abstract][Full Text] [Related]
12. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
von Eiff C; Peters G
J Antimicrob Chemother; 1999 Apr; 43(4):569-73. PubMed ID: 10350389
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae.
Mason EO; Lamberth LB; Kaplan SL
Antimicrob Agents Chemother; 1996 Apr; 40(4):1039-40. PubMed ID: 8849225
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.
Kaatz GW; Seo SM
Antimicrob Agents Chemother; 1996 Mar; 40(3):799-801. PubMed ID: 8851617
[TBL] [Abstract][Full Text] [Related]
15. The in-vitro activity of linezolid (U-100766) and tentative breakpoints.
Wise R; Andrews JM; Boswell FJ; Ashby JP
J Antimicrob Chemother; 1998 Dec; 42(6):721-8. PubMed ID: 10052894
[TBL] [Abstract][Full Text] [Related]
16. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
17. In vitro antimicrobial activity of linezolid tested against vancomycin-resistant enterococci isolated in Brazilian hospitals.
Reis AO; Cordeiro JC; Machado AM; Sader HS
Braz J Infect Dis; 2001 Oct; 5(5):243-51. PubMed ID: 11779450
[TBL] [Abstract][Full Text] [Related]
18. [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci].
Aktaş G; Bozdoğan B; Derbentli S
Mikrobiyol Bul; 2012 Jul; 46(3):359-65. PubMed ID: 22951648
[TBL] [Abstract][Full Text] [Related]
19. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe).
Bolmstrom A; Ballow CH; Qwarnstrom A; Biedenbach DJ; Jones RN
Clin Microbiol Infect; 2002 Dec; 8(12):791-800. PubMed ID: 12519352
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.
Wagenlehner FM; Lehn N; Witte W; Naber KG
Chemotherapy; 2005 May; 51(2-3):64-9. PubMed ID: 15870498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
